A PHASE 3, OPEN-LABEL RANDOMIZED TRIAL TO COMPARE RINATABART SESUTECAN VERSUS INVESTIGATOR'S CHOICE OF CHEMOTHERAPY IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER: RAINFOL™-02 (ENGOT-OV86/GOG-3107)

作者：Angeles Alvarez Secord, Elizabeth Lee, Michael J. Sundborg, Destin Black, David Starks, Edwin Alvarez, David R. Spigel, Noelle Cloven, Lynne M. Knowles, Anton Melnyk, William E. Winter, Michael McCollum, Peter Lim, Robert Neff, David M. O’Malley, Felix Hilpert, Dagmara Klasa-Mazurkiewicz, María Quindós Varela, Laurence Gladieff, Beryl Manning‐Geist, Bhavana Pothuri, Ibrahima Soumaoro, Yan Liu, Christian Marth · 发表于：International Journal of Gynecological Cancer · 年份：2025 · DOI：10.1016/j.ijgc.2025.102614 · 被引用次数：1 · 研究领域：Inflammatory Biomarkers in Disease Prognosis、Effects of Radiation Exposure、Chemotherapy-induced organ toxicity mitigation